Momelotinib(Ojjaara)

Momelotinib is a prescription drug approved by the U.S. Food and Drug Administration (FDA) on September 15, 2023. It acts on the JAK1/JAK2 signaling pathway and the JAK2V617F mutant. Use of this medication must be strictly under the guidance of a physician.

Target of Action

JAK1/JAK2 signaling pathway and JAK2V617F mutant

Dosage and Administration

Route and frequency of administration for Momelotinib: Oral, once daily.

Dosage adjustment of Momelotinib should be based on the patient's actual condition; specific circumstances require consultation with a physician and adherence to medical advice.

Recommended reading: Dosage and Administration of Momelotinib

Side Effects

Common side effects: Low platelet count, bleeding, bacterial infection, etc.

Serious side effects: Risk of infection, low platelet and white blood cell counts, liver problems, etc.

Reference article: Side Effects of Momelotinib

Use in Special Populations

Pregnancy: If you are pregnant or plan to become pregnant, Momelotinib may harm your unborn baby.

Breastfeeding: If you are breastfeeding or plan to breastfeed, it is not known whether Momelotinib passes into breast milk. You should not breastfeed during treatment with Momelotinib and for 1 week after the last dose.

Daily Precautions

1.Inform patients that Momelotinib tablets should be swallowed whole, with or without food. The tablet should not be broken, crushed, or chewed. Inform patients that if a dose of Momelotinib is missed, the next scheduled dose should be taken the following day. Inform patients to store Momelotinib in the original bottle with the desiccant to protect from moisture, and to keep the bottle tightly closed after each opening.

2.Inform patients that Momelotinib may increase the risk of infection, including COVID-19. Inform patients to contact their clinician immediately if any signs or symptoms of infection occur.

3.Inform patients that thrombocytopenia and neutropenia are risks during treatment with Momelotinib. Inform patients that monitoring of complete blood count (CBC), including platelet count and neutrophil count, is recommended before and during treatment with Momelotinib.

from FDA,2023.09